Armando Santoro
0000-0003-1709-9492
Publication & Citation Trends
Publications
0 total
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses.
Cited by 6
Semantic Scholar
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma
Cited by 0
Semantic Scholar
GS-005 Outcomes by liver function in patients with unresectable hepatocellular carcinoma treated with nivolumab plus ipilimumab vs lenvatinib or sorafenib in the CheckMate 9DWtrial
Cited by 2
Semantic Scholar
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. OA
Cited by 125
Semantic Scholar
Erratum: Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial.
Cited by 0
Semantic Scholar
Phase Ib study of gevokizumab (GEVO) in combination with standard-of-care (SoC) anticancer therapies in patients (pts) with metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC), and metastatic renal cell cancer (mRCC).
Cited by 0
Semantic Scholar
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040. OA
Cited by 66
Semantic Scholar
Research Topics
Lymphoma Diagnosis and Treatment
(402)
Lung Cancer Treatments and Mutations
(268)
Chronic Lymphocytic Leukemia Research
(173)
CAR-T cell therapy research
(167)
Colorectal Cancer Treatments and Studies
(162)
Affiliations
Università Cattolica del Sacro Cuore
University of Pisa
Roche (Switzerland)
Marche Polytechnic University
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”